Why Nevro Corp (NVRO) Stock is a Compelling Investment Case
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Small-Cap Growth Fund posted a return of 34.59% for the quarter, outperforming its benchmark, the Russell 2000 Growth Index which returned 30.59% in the sa
Insider Monkey · 3天前
Nevro (NVRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 5天前
Nevro to Report Second Quarter 2020 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 a
PR Newswire · 07/20 11:00
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
Investor confidence is high on Nevro (NVRO), thanks to solid prospects
Zacks · 07/10 12:46
Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to $145
Morgan Stanley maintains Nevro (NYSE:NVRO) with a Overweight and raises the price target from $135 to $145.
Benzinga · 06/18 11:51
Edited Transcript of NVRO earnings conference call or presentation 5-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/13 13:59
Edited Transcript of NVRO earnings conference call or presentation 25-Feb-20 9:30pm GMT
Q4 2019 Nevro Corp Earnings Call
Thomson Reuters StreetEvents · 06/08 16:33
UBS Upgrades Nevro to Neutral, Raises Price Target to $132
UBS analyst Matthew Taylor upgrades Nevro (NYSE:NVRO) from Sell to Neutral and raises the price target from $100 to $132.